Xilio Therapeutics Inc Net Income per Employee (XLO), current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Sales per Employee
• Income per Employee
• Inventory Turnover
• Asset Turnover
• Receivables Turnover
Xilio Therapeutics Inc   (NASDAQ: XLO)
 

Xilio Therapeutics Inc Net Income per Employee

XLO's Quarterly Results, Trends, Rankings, Statistics
Xilio Therapeutics Inc recorded a cumulative net loss of $-3 million during 12 month ending in the second quarter 2026.
The Healthcare sector has seen Xilio Therapeutics Inc achieved the highest income per employee. While income per employee remained unchanged compared to the previous quarter at no. .


What is Income per Employee Ratio?





Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

XLO Net Income per Employee (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Net Income Change - - - - -
Net Income per Employee (TTM) $ -34,697 49,158 - -346,816 -531,289
XLO's Total Ranking # # # # # 3907
Seq. Net Income Change - - - - -

XLO Company Profile >> Back to XLO Efficiency Comparisons >> Compare XLO Net Income per Employee to its Competitors

XLO Net Income per Employee Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall Market #

Net Income per Employee Statistics
High Average Low
$ -213,829 $ -853,415 $ -1,177,829
(Sep 30 2021)   (Mar 31 2023)




  News about Xilio Therapeutics Inc Income per employee

Xilio Therapeutics: Navigating Strategic Reprioritization Amidst Financial Challenges



In a recent press release, Xilio Therapeutics Inc unveiled its strategic portfolio reprioritization plan, highlighting its focus on advancing clinical-stage programs for two promising tumor-activated therapies, XTX301 and XTX101. The company aims to leverage its innovative research platform for developing bispecific and cell engager molecules. However, amidst these ambitious initiatives, Xilio Therapeutics also grapples with significant financial setbacks, as it records a cumulative net loss of $-81 million for the twelve-month period ending in Q3 2023. This article will outline the facts surrounding these events and assess their impact on the company s future.
Article
Xilio Therapeutics Inc, a renowned biotechnology company specializing in groundbreaking cancer therapies, recently announced its strategic portfolio reprioritization plan. With a sharp focus on advancing clinical-stage programs for two tumor-activated therapies, namely XTX301 and XTX101, the company aims to revolutionize cancer treatment. XTX301, an innovative tumor-activated Interleukin-12 (IL-12), and XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, exhibit immense potential in targeting and treating various cancer types.




Companies with similar Income per Employee for 12 month ending Jun 30 2026, within Healthcare Sector Income per Employee Income 12 month ending Jun 30 2026Number of Employees Jun 30 2026


Date modified: 2026-09-04T10:54:16+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.